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Aims To evaluate the inﬂuence of achieving secondary prevention target treatment goals for cardiovascular (CV) risk
factors on clinical outcomes in patients with prior coronary artery bypass surgery (CABG).
Methods
and results
Accordingly, we analysed treatment to target goals in patients with prior CABG and atherothrombotic disease or
known risk factors (diabetes, hypertension, hypercholesterolaemia, smoking, obesity) enrolled in the global REduction
in Atherothrombosis for Continued Health (REACH) Registry, and their association with 1 year outcomes. A total of
13 907 of 68 236 patients (20.4%) in REACH had a history of prior CABG, and 1 year outcomes data were available for
13 207 of these. At baseline ,25, 25–,50, 50–,75, and  75% risk factors were at goal in 3.7, 12.9, 31.7, and 51.7%
of patients, respectively. One-year composite rates of CV death, non-fatal MI, non-fatal stroke were inversely related to
the proportion of risk factors at goal at baseline (age, gender, and region adjusted rates 6.1, 5.6, 5.2, and 4.3% of patients
with ,25, 25–,50, 50–,75, and .75% risk factors at goal, respectively; P for trend 0.059).
Conclusion Risk-factor control varied greatly in CABG patients. Although CABG patients are frequently treated with appropriate
therapies, these treatments fail to achieve an adequate level of prevention in many. This failure was associated with a
trend for worse age-, gender-, and region-adjusted clinical outcomes. Thus, perhaps secondary prevention after
CABG needs to focus on more comprehensive modiﬁcation of risk factors to target goals in the hope of preventing
subsequent CV events, and represents an opportunity to improve CV health.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
Keywords Coronary disease † Bypass † Revascularization † Stroke † Risk factors
Introduction
Coronary artery bypass surgery (CABG) remains an important
method for coronary revascularization in patients with CAD,
accounting for more than 300 000 procedures in United States
per year, and even more on a global scale.
1 Recurrent ischaemic
events occur frequently in these patients due to graft attrition as
well as progression of native CAD.
2–5 The role of secondary pre-
vention measures and risk-factor control in reducing recurrent
ischaemic events is well established
6–10 and is reiterated in prac-
tice guidelines for both the American College of Cardiology/
American Heart Association
11 and the European Society of
Cardiology.
12 Despite unequivocal evidence favouring the use of
secondary prevention measures and risk factor control in patients
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therapies after CABG has been reported.
13 Additionally, even
among patients receiving evidence-based treatments, not all
achieve the target goals of secondary prevention. However, the
proportion of patients achieving recommended goals while on
appropriate treatment and the implications of not achieving such
targets in patients who have had CABG remain less well known.
The main purpose of the current investigation was to analyse
information on patients with a history of CABG enrolled in the
REACH Registry
14,15 and to evaluate the variation in the pro-
portion of patients that fail to attain their target goals for second-
ary prevention at baseline (i.e. control of hypertension, diabetes,
increased cholesterol, smoking cessation, and attainment of BMI
in the normal range) and their 1 year outcomes.
Methods
Patient population
A total of 68 236 patients were initially enrolled in the REACH Registry
with data on baseline risk factors collected in 2003–2004. In brief, the
Registry recruited outpatients in 44 countries across six major regions
(Latin America, North America, Europe, Asia, the Middle East, and
Australia) from .5000 physician outpatient practices. Patients aged
 45 years with already existing at least three atherothrombotic risk
factors or documented cardiovascular disease, CAD (that included
patients with prior CABG), or PAD were enrolled.
14,15 To ensure
representative inclusion of the overall population in each practice
setting it was attempted to recruit consecutively at each site;
however, because of the large number of potential study candidates
at sites, no enrolment logs were maintained as part of this study. A
limited time period was set for the duration of enrolment at each prac-
tice setting—approximately 5 days from the ﬁrst to the last patient
enrolled—suggesting near, if not consecutive, patient enrolment.
Enrolment occurred worldwide between December 2003 and June
2004; because of regulatory requirements in Japan, the enrolment in
that country was delayed and occurred between August 2004 and
December 2004.
14,15
We focused on 13 907 patients with prior CABG enrolled in
REACH. For the current study, we included 13 207 (95%) patients
with CABG who had complete information available on 1 year out-
comes. All other information was complete in these 13 207 patients
with the exception of age and/or gender in minority [n ¼ 57 (0.4%)].
These patients were not excluded from the analysis.
Evaluations
Medical history, risk factors, demographic information, and manage-
ment were collected at baseline, and clinical events that occurred
during the follow-up period [of up to 4 years: 1 year (12+3
months), 2 year (21+3 months), 3 year (33+3 months), 4 year
(45+3 months)] are recorded. For this current study, we restricted
our analysis to those patients who had a documented history of
prior CABG and had 1 year of follow-up data.
14,15
Risk factors
The risk factors consisted of those that were documented in the
medical record or for which patients were receiving treatment at
the time of study enrolment. Similarly, whether risk factors were at
goal or not were deﬁned based on their value at baseline visit and
risk factors assessment was not performed at follow-up. Five risk
factors were analysed: a history of diabetes, hypertension, hyperlipi-
daemia, smoking status, and BMI. Uncontrolled risk factors at baseline
were deﬁned as blood sugar .126 mg/dL, BP .140/90 mmHg
(except among people with diabetes in whom this was deﬁned as
BP .130/80 mmHg), total cholesterol .200 mg/dL, continued
smoking ( 5 cigarettes per day), and obesity (BMI .30 kg/m
2).
The proportion of risk factors at goal was calculated for each patient
as follows: Number of risk factors at goal in a given individual/total
number of risk factors in that individual   100. Then as ﬁve risk
factors were taken into account ,25% risk factor at goal¼0o r1
among 5, or 0 among 4, 3, 2 or 1; 25 to ,50% ¼ 2 among 5, and
1 among 4 or 3; 50 to ,75% ¼ 3 among 5 or 2 among 4 or 3, or 1
among 2; and  75% ¼ 4 or 5 among 5, 3 or 4 among 4, 3 among 3,
2 among 2, and 1 among 1.
Study outcomes
For the present analysis, the outcomes of interest included the follow-
ing events at 1 year: (1) combined end-point of cardiovascular death
(including fatal stroke, fatal MI, and other cardiovascular death), non-
fatal stroke (ischaemic or haemorrhagic), non-fatal MI, and hospitaliz-
ations for atherothrombotic events (transient ischaemic attack,
unstable angina, and other ischaemic arterial event including worsening
of PAD); (2) combination of non-fatal stroke, non-fatal MI, or cardio-
vascular death; (3) cardiovascular death; and (4) all-cause death. The
association of the proportion of risk factors at goal at baseline was
then evaluated with 1 year outcome.
Study setting and site selection
Site selection was undertaken to reﬂect different practices of manage-
ment of patients with atherothrombotic diseases around the world.
Physicians (family and general practitioners, cardiologists, neurologists,
angiologists, vascular surgeons, and endocrinologists) were selected at
a country level, based on available data. The studies had to be pub-
lished, population-based, and endorsed by national or international
scientiﬁc societies. Physician selection was designed to provide a distri-
bution across regions and locations; i.e. urban, suburban, or rural areas.
Because the physician selection was done at a national level, rationale
and guidelines for physician selection were set and disseminated to
National Coordinators and local project managers. Feedback from
each participating country was centralized to check the quality and
the homogeneity of the physician selection between countries, and
the Steering Committee validated physician selection before the
start of the inclusion period, and the local National Coordinators
served as the ﬁnal arbitrators of sites and distribution of patient popu-
lation based on the above general criteria described. Each physician
recruited a maximum of 15 patients (up to 20 patients in the US).
14,15
Statistical analysis
Data are summarized as mean and standard deviation for continuous
variables and as counts and percentages for categorical variables. No
imputation was done for missing variables and denominators reﬂect
cases reported. Univariate comparisons were made using Student’s
t-test for continuous variables and x
2 test for the categorical variables.
All event rates are calculated with a Cox Model after adjustment for
age, sex, and region as proportions [rate ¼ (12survival)   100]. The
Cochran–Mantel–Haenszel test was used to calculate the P-values
for trends of adjusted outcomes. All statistical analyses were per-
formed using SAS version 9.1.3 (SAS Institute, CARY, NC) and were
considered signiﬁcant at the 95% conﬁdence limit using two-sided
tests or two-sided conﬁdence intervals.
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Baseline clinical features and risk factors
Of13 907(20.38%)patientswithahistoryofCABGatbaselinevisit,1
yearfollow-upinformationwasavailableinthe majority(n ¼ 13 207,
95%).TheregionalprevalenceofCABGpatientsintheREACHpopu-
lation at baseline ranged from 26.79% (6964) in North America to
10.72% (1146) in Asia, with rates for Western Europe (n ¼ 3075,
17.94%) and the rest of the world (n ¼ 2022, 18.14%) in between
that of USA and Asia. Individual risk factors treated to goal in post-
CABG patients varied considerably. This was lowest for diabetes
control (43.30%) and highest for smoking cessation (86.13%). The
proportion of patients with BMI .30 kg/m
2 (69.89%), cholesterol
at goal among those with high cholesterol (75.01%) and BP at goal
among those with high blood pressure (76.30%) was in between
that for the above two risk factors.
Failure to achieve at least 50% of simple secondary prevention
goals was present in 16.58% of CABG patients (Table 1). This
number increased to almost 50% when we considered CABG
patients who failed to achieve 75% of secondary prevention goals.
Patients with  75% of risk factors at goal were more likely to be
older, Caucasian, male, have a lower BMI, and smaller waist circum-
ferencewhencomparedwiththosewith ,25%riskfactorsatgoal.In
contrast, fewer patients with  75% of risk factors at goal had dia-
betes,hyperlipidaemia,priorMI,priorpercutaneouscoronaryinter-
ventions, prior stroke, prior PAD, and prior cardiovascular disease.
Similarly, these patients had lower systolic and diastolic BP, lower
total cholesterol, and lower triglyceride levels compared with
those with ,25% risk factors at goal.
Risk factors at goal and outcomes
There was a trend for higher 1 year events as the number of risk
factors increased (Figure 1). Risk factors at goal and outcomes are
shown in Tables 2 and 3. Most event rates tended to be lower
(either signiﬁcantly or non-signiﬁcantly) when patients treated for
a given risk factor were at goal compared with those treated but
not at goal at baseline (Table 2). Furthermore, a trend for an
inverse relationship was observed with the percentage of risk
factors at goal and 1 year event rates in CABG patients (Table 3,
Figure 2) with the lower event rates among those with a greater
percentage of risk factors at goal at baseline (a non-signiﬁcant
trend for some events). Additionally, this inverse relationship
between the percentage of risk factors at goal at baseline and 1
year adverse clinical events (for some events a non-signiﬁcant
trend) was demonstrated among patients regardless of the
number of their underlying risk factors (data not shown).
..................................................................................................................
...............................................................................................................................................................................
Table 1 Baseline characteristics in coronary artery bypass surgery patients among percentage of risk factors at goal
Percentage of risk factors at goal
Total ,25% 25–50% 50–,75%  75% P-value
n (%) 13 207 (100) 489 (3.70) 1701 (12.88) 4188 (31.71) 6829 (51.71)
Age, years, mean+SD 69.6+9.5 65.2+9.4 66.7+9.2 69.1+9.4 70.9+9.3 ,0.0001
Male, n (%) 10 163 (77.00) 328 (67.91) 1219 (71.66) 3159 (75.45) 5457 (79.92) ,0.0001
Caucasian, n (%) 9564 (77.02) 343 (74.73) 1229 (76.67) 3012 (76.56) 4980 (77.56) 0.3934
BMI . 30 kg/m
2, n (%) 3922 (30.11) 444 (94.07) 1064 (63.30) 1673 (40.64) 741 (10.97) ,0.0001
Waist circumference, cm, mean+SD 99.2+15.0 109.2+12.6 105.2+15.8 100.7+15.1 96.0+13.9 ,0.0001
Hypertension, n (%) 10 643 (80.60) 402 (82.38) 1424 (83.72) 3258 (77.81) 5559 (81.40) ,0.0001
Diabetes mellitus, n (%) 5467 (41.40) 359 (73.42) 1137 (66.84) 1864 (44.52) 2107 (30.85) ,0.0001
Hyperlipidaemia, n (%) 10 912 (82.70) 398 (81.56) 1471 (86.58) 3471 (82.94) 5572 (81.68) ,0.0001
Current smoker, n (%) 1119 (8.74) 140 (29.79) 335 (20.64) 468 (11.58) 176 (2.64) ,0.0001
Prior myocardial infarction, n (%) 7195 (55.57) 294 (61.25) 972 (58.66) 2261 (55.09) 3668 (54.69) 0.0017
Prior heart failure, n (%) 2951 (22.82) 128 (27.35) 432 (25.91) 902 (21.98) 1489 (22.25) 0.0006
Prior percutaneous coronary interventions, n (%) 4032 (30.96) 184 (38.17) 517 (30.98) 1265 (30.67) 2066 (30.62) 0.0066
Prior stroke, n (%) 1417 (10.89) 87 (18.05) 226 (13.50) 440 (10.67) 664 (9.86) ,0.0001
Prior cerebrovascular disease, n (%) 2119 (16.04) 110 (22.49) 313 (18.40) 667 (15.93 1029 (15.07) ,0.0001
Prior peripheral arterial disease, n (%) 1773 (13.42) 86 (17.59) 274 (16.11) 596 (14.23) 817 (11.96) ,0.0001
Diastolic BP, mmHg, mean+SD 75.7+10.9 85.7+10.4 81.3+11.8 76.3+10.9 73.3+9.6 ,0.0001
Systolic BP, mmHg, mean+SD 133.6+18.8 147.2+19.9 141.3+20.5 134.2+18.8 130.4+17.2 ,0.0001
Serum creatinine, mg/dL, mean+SD 1.2+0.7 1.2+0.8 1.2+0.8 1.2+0.7 1.2+0.7 0.8072
Total cholesterol, mg/dL, mean+SD 178.9+42.6 228.2+45.3 207.2+50.7 188.5+44.5 166.2+33.1 ,0.0001
Triglycerides, mg/dL, mean+SD 157.4+92.0 222.6+125.1 199.9+108.9 171.5+100.3 139.0+75.4 ,0.0001
Ankle brachial index, mean+SD 0.9+0.2 0.9+0.2 0.9+0.2 0.9+0.2 0.9+0.2 0.4484
Carotid medial thickness, mm, mean+SD 1.3+0.7 1.3+0.7 1.3+0.7 1.4+0.7 1.3+0.7 0.7831
Microalbuminuria, mean+SD 106.7+431.9 153.5+404.6 158.3+522.7 110.2+556.3 83.071+279.6 0.0545
BMI, body mass index; BP, blood pressure.
R.H. Mehta et al. 3054Global variations in prevalence
and proportion of risk factors
at goal and outcomes
Table 4 shows that risk factors at goal and outcomes demonstrated
geographical variations among patients with CABG. Prevalence of
risk factors in patients with prior CABG was in general higher
among North American patients. Achievement of target goals for
risk factors also varied according to the region and was worse
for almost all risk factors for the rest of the world compared
with US, Western Europe, and Asia. All adverse event rates
were higher among patients in the rest of the world compared
with other cohort.
Discussion
Our study ﬁndings
The major ﬁnding of this study in patients with a history of CABG
was that the failure to achieve target goals varied widely across
various participating sites, among different risk factors and across
different regions. There was a suggestion that this variation in
risk factor control among CABG patients was associated with vari-
ation in outcomes. Thus, a failure to achieve target goal for differ-
ent risk factors was associated with a trend (for some event
non-signiﬁcant) towards increase in 1 year adverse cardiovascular
event rates. This relationship also showed a trend for dose–
response linkage with higher clinical adverse event rates among
patients who had a lower proportion of risk factors that were at
goal. Additionally, risk factors at target goal for that risk factor
were associated with a trend (non-signiﬁcant for some events)
for better outcomes than those just treated but not at goal.
Thus, perhaps achieving target goals for risk factors appeared to
be more important than merely treating patients without reaching
this goal. Furthermore, the trend for inverse relationship between
risk factors at goal and 1 year outcomes was observed for all
patients irrespective of the number of the underlying risk factors
that they had (even in those with four or ﬁve risk factors). This
suggests that reducing the variability and increasing the modulation
of risk factors to their target goal is important for all CABG
patients, who are at high atherothrombotic risk, and may have
the potential to decrease their long-term adverse event rates.
Our study suggests that in patients who had previous CABG, the
vast majority had a clustering of atherothrombotic risk factors, i.e.
diabetes, hypertension, high cholesterol, BMI . 30 kg/m
2, and
smoking, with 95.3% having one or more of these factors. A
trend towards higher 1 year adverse clinical events rates of
cardiovascular mortality; all-cause death; composite of death, non-
fatal stroke, and non-fatal MI; and this composite combined with
repeat hospitalization, were noted as the number of risk factors
increased. Despite the ubiquitous presence of risk factors among
CABG patients and a suggestion of a link between risk factors
and adverse events at 1 year, our data indicate that there is a
wide variation in treatments to goal of these risk factors. Particu-
larly, in such a population with advanced atherothrombosis at
high risk for subsequent event, only 50% of patients had  75%
of their risk factors at treatment goal.
Consistent with that reported previously for the overall patients
enrolled in REACH,
15 we also found striking global differences in
the prevalence of risk factors and treatments of these risk
factors to achieve target goals among patients with prior CABG.
Consistent with the overall ﬁndings of this investigation, the
region with the highest proportion of individual patient risk
factors not at goal had also a trend for the worst 1 year adverse
event rates. These data suggest that targeting various regions for
not only improving treatments of risk factors, but also perhaps
to strive and attain target goals to minimize variability in control
of risk factors, may have the potential for reducing the geographical
variations in adverse outcomes.
Findings of previous studies
Previous observational studies have reported signiﬁcant variability
in guideline-based care for CABG patients.
13,16–18 This variability
and lack of adherence to appropriate treatments has been much
greater for patients with CABG than those without CABG.
Additionally, the PREVENT-IV trial investigators demonstrated a
dose-dependent relationship between adherence to guidelines
and outcomes among patients undergoing CABG.
16 In PREVENT
IV, the 2 year composite event of death or MI increased from
4.2% in patients taking all their indicated medications to 8.2% in
those taking less than half their medications [adjusted HR 1.69
(95% CI 1.12–2.55)].
16
Similarly, Vanasse et al.
17 examined a population of patients  65
years of age in Quebec, Canada who survived their MI and demon-
strated that 2 year cardiovascular death rates increased from 4.5 to
15.5%, and non-cardiovascular death rates increased from 6.4 to
14.9% when medication use (aspirin, beta-blockers, angiotensin
converting enzyme inhibitors, statins) decreased from 4 to 0 in
patients undergoing CABG or percutaneous coronary interven-
tion. These ﬁndings are consistent with studies that have examined
the overall CAD population as well as those with congestive heart
failure, which have shown that performance measures have a major
inﬂuence on cardiovascular outcomes.
19
Figure 1 One year event rates (adjusted for age, sex, region)
according to the number of risk factors in coronary artery
bypass surgery patients showing that as the number of risk
factors increased the event rates also increased.
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Table 2 Risk factors and 1 year outcomes in coronary artery bypass surgery patients according to individual risk factors adjusted for age, sex, and region
Risk factor N Cardiovascular death/MI/stroke Cardiovascular death All-cause death Cardiovascular death/MI/stroke or
hospitalization
n %9 5 % C I n % 95% CI n %9 5 % C I n %9 5 % C I
No diabetes 7739 278 3.87 [2.92; 4.80] 116 1.59 [1.01; 2.17] 174 2.43 [1.72; 3.13] 963 12.42 [10.85; 13.95]
Diabetes-overall 5467 304 6.28 [4.79; 7.75] 143 3.05 [1.98; 4.10] 210 4.38 [3.14; 5.59] 952 17.57 [15.41; 19.66]
Diabetes-not treated
a 591 28 4.95 [2.56; 7.26] 13 2.34 [0.75; 3.96] 23 3.90 [1.77; 5.98] 86 15.10 [11.14; 18.87]
Diabetes-treated
a 4860 276 6.55 [4.49; 8.53] 130 3.28 [1.85; 4.72] 187 4.61 [2.95; 6.25] 861 17.84 [14.84; 20.71]
Diabetes-treated not at goal
a 2411 134 6.26 [3.86; 8.65] 58 2.73 [1.45; 4.03] 87 4.09 [2.45; 5.72] 424 17.68 [13.91; 21.25]
Diabetes-treated at goal
a 1661 87 5.66 [3.35; 7.97] 45 2.97 [1.51; 4.45] 65 4.17 [2.42; 5.91] 275 16.52 [12.78; 20.06]
No hypertension 2562 94 4.22 [2.96; 5.47] 54 2.54 [1.48; 3.60] 71 3.24 [2.10; 4.36] 302 12.28 [10.34; 14.17]
Hypertension-overall 10 643 488 4.99 [3.86; 6.10] 205 2.09 [1.39; 2.79] 313 3.20 [2.34; 4.05] 1612 15.07 [13.31; 16.80]
Hypertension-treated
a 10 550 486 5.03 [3.78; 5.03] 205 2.13 [1.32; 2.92] 312 3.24 [2.27; 4.19] 1603 15.93 [14.78; 17.06]
Hypertension-not treated
a 90 2 2.26 [0.00; 5.35] 0 NE
b NE
b 1 1.04 [0.00; 3.05] 8 9.49 [2.86; 15.66]
Hypertension-treated not at goal
a 2497 128 5.78 [4.04; 7.48] 45 2.31 [1.20; 3.41] 67 3.50 [2.15; 4.82] 427 16.79 [14.22; 19.27]
Hypertension-treated at goal
a 8031 358 4.81 [3.58; 6.02] 160 2.08 [1.28; 2.87] 245 3.18 [2.21; 4.14] 1174 14.55 [12.65; 16.41]
No hyperlipidaemia 2282 144 6.78 [4.95; 8.56] 78 3.65 [2.24; 5.02] 112 5.16 [3.55; 6.74] 355 16.58 [14.11; 18.97]
Hyperlipidaemia-overall 10 912 437 4.42 [3.41; 5.40] 181 1.86 [1.24; 2.47] 272 2.78 [2.03; 3.53] 1558 14.16 [12.50; 15.78]
Hyperlipidaemia-not treated
a 99 5 5.64 [0.29; 10.74] 4 4.28 [0.00; 8.80] 4 4.25 [0.00; 8.64] 14 13.45 [6.36; 19.99]
Hyperlipidaemia-treated
a 10 805 430 4.36 [3.22; 5.49] 176 1.80 [1.12; 2.51] 267 2.75 [1.88; 3.62] 1540 14.11 [12.26; 15.92]
Hyperlipidaemia-treated not at goal
a 2235 94 4.85 [3.11; 6.54] 29 1.68 [0.72; 2.67] 48 2.79 [1.51; 4.08] 366 15.96 [13.19; 18.64]
Hyperlipidaemia-treated at goal
a 6770 253 4.08 [2.83; 5.08] 101 1.57 [0.85; 2.32] 156 2.42 [1.52; 3.33] 906 13.27 [11.26; 15.23]
Non-smoker ever 4741 211 4.59 [3.40; 5.75] 96 2.11 [1.30; 2.90] 129 2.82 [1.93; 3.69] 622 12.74 [10.98; 14.46]
Smoker-former or current 8069 354 5.03 [3.84; 6.21] 157 2.25 [1.46; 3.04] 246 3.50 [2.52; 4.47] 1223 15.53 [13.63; 17.38]
Smoker-current 1119 63 7.44 [4.58; 10.18] 22 2.79 [1.10; 4.47] 39 5.07 [2.70; 7.36] 208 19.23 [15.49; 22.79]
Smoker-former 6950 291 4.60 [3.87; 5.33] 135 2.16 [120; 3.12] 207 3.30 [2.15; 4.44] 1015 14.99 [12.69; 17.20]
BMI .30 kg/m
2 3922 149 4.46 [3.26; 5.65] 66 2.10 [1.28; 2.93] 97 3.08 [2.08; 4.07] 591‘ 14.65 [12.68; 16.58]
BMI  30 kg/m
2 9105 426 5.00 [3.84; 6.14] 192 2.24 [1.48; 2.99] 282 3.26 [2.36; 4.14] 1304 14.57 [12.80; 16.29]
MI, myocardial infarction; BMI, body mass index; N, number of patients at risk; n, number of events; (%), percentage of ‘at risk’ patients who experienced an event.
aNumbers do not add up due to missing variables.
bNE, the number of events is ,5, so the event rates are non-estimable.
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6Almost all these studies have focused on the use of evidence-
based medications and life-style modiﬁcation goals and their
relationship with patient outcomes.
13,16–18 No prior study has
focused on the association of achieving target goals with these
therapies with patient outcomes. Thus, the present study adds to
this existing knowledge by demonstrating that beyond mere use
of evidence-based treatment, there is wide variation in the use
of treatments to achieve target goals that may be associated with
variation in clinical outcomes in patients with CABG. The widely
used performance systems for assessing quality are based on the
concept that more consistent use of selected guideline-based
therapies leads to better outcomes. Even quality improvement
initiatives have focused primarily on improving the use of these
therapies.
20 Our data suggest that perhaps guideline-based care
should not be limited to mere adherence to these process
measures, but should aim for their use to achieve target goals to
have the maximum impact on patients’ outcomes.
Clinical implications
Our study ﬁndings have clinical implications for patients with
CABG and CAD in general. Coronary heart disease remains the
leading cause of morbidity and mortality in both developed and
developing countries.
1,21 While new therapies are continuously
evolving to meet the challenge of this global health care burden,
better application of available therapy speciﬁcally to targeted
goals may represent the most cost-effective option for saving
lives and improving outcomes. While a modest increase in the
use of evidence-based medicine has been shown to result in
saving 50 000 or more lives per year,
19 our data suggest a potential
for saving even more lives if the wide variability in the use of
therapies to targeted goals for secondary prevention is minimized.
Limitations
Our study has limitations. First, it is observational and non-
randomized, therefore causality should be inferred with caution.
We cannot account for the inﬂuence of unmeasured confounders
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Figure 2 One year event rates (adjusted for age, sex, and
region) according to the percentage of risk factors at goal
among coronary artery bypass surgery patients. Note the
inverse relationship between the percent of risk factors at goal
and outcomes. *P-value for trend.
Risk factor control and outcomes after CABG 3057on treatment and outcomes, particularly patient and physician pre-
ferences for treatments. We evaluated patients at baseline to see
if they were at target goals and did not examine whether these
goals changed over 1 year—a time-frame used for clinical events.
Changes in target goals for better or worse may have had an inﬂu-
ence on outcomes. We are unable to adjust for the time between
CABG and enrolment in REACH that could have potential impact
on adverse events as we do not have the date of previous CABG.
Although we deﬁne obesity as .30 kg/m
2 for uniformity, this
cutoff may differ among patients in different parts of the world.
Finally, there may be a selection bias as we examined patients
enrolledintheREACHRegistrythatwereenrolledatmotivatedout-
patient practices and failure to achieve target goals may be even
higher in the community than that observed in the REACH Registry.
Weacknowledgethatriskfactorscontrolandoutcomesarelikelyto
varyacrosssites,countries,andcontinentsinthislarge,international,
multi-centrestudy.Thusour ﬁndingsneedto be conﬁrmedand vali-
dated over a more global population before generalizing them.
Conclusions
Patients remain at high risk of subsequent major cardiovascular
events after CABG. Despite this, there is wide variation in post-
CABG secondary prevention care around the world. Although
patients are frequently treated after CABG with appropriate
therapies, these treatments fail to achieve an adequate level of
prevention in many. This failure was associated with a trend
towards worse age, gender, and region adjusted clinical outcomes
at 1 year. Thus, secondary prevention after CABG may have to be
focused on more comprehensive risk factor modiﬁcations to bring
patients to target goals and reduce the existing variability in risk
factor control. This strategy may have the potential to prevent
further cardiovascular events, and perhaps represents an opportu-
nity to save many lives and improve cardiovascular health.
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Table 4 Risk factors and 1 year outcomes according to regions among coronary artery bypass surgery patients
North America Western Europe Asia Rest of World
n 6964 3075 1146 2022
Diabetes mellitus, n (%) 3192 (45.84) 1082 (35.19) 551 (48.08) 642 (31.75)
Diabetes not at goal (in diabetic
patients), n (%)
1552 (55.07) 498 (58.45) 263 (58.57) 293 (61.43)
Hypertension, n (%) 5875 (84.37) 2368 (77.03) 836 (72.95) 1564 (77.35)
Blood pressure not at goal (in
hypertensive patients), n (%)
951 (16.22) 795 (33.69) 245 (29.38) 526 (33.67)
Hyperlipidaemia, n (%) 6032 (86.75) 2561 (83.34) 703 (61.34) 1616 (79.92)
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patients with history of high
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Former or current smoker,
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4323 (63.63) 1902 (65.34) 642 (57.99) 1202 (60.16)
Current smoker among former
or current smoker, n (%)
618 (14.30) 258 (13.56) 94 (14.64) 149 (12.40)
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death); n, [% – (95% CI)]
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Cardiovascular death/MI/
stroke; n, [% – (95% CI)]
323, [4.462(3.77; 5.15)] 147, [5.302(4.24; 6.35)] 19, [4.242(2.72; 5.74)] 125, [5.532(4.26; 6.79)]
Cardiovascular death/MI/
stroke/hospitalization;
n, [% – (95% CI)]
1017, [15.182(14.00; 16.35)] 485, [16.642(15.12; 18.14)] 43, [7.582(6.00; 9.13)] 370, [16.912(15.14; 18.65)]
BMI, body mass index; MI, myocardial infarction.
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